GeoVax has 3-4 Vaccine Candidates in development to respond to the COVID-19 Pandemic. Here is some of the media coverage.

Print:

[A COVID-19 Vaccine, Outsourcing, And Made In The USA]

Developing Covid-19 Vaccines at Pandemic Speed - GeoVax listed- Nonreplicating Vector



Vaccine Platforms, Their Attributes, and the Status of Vaccine Candidates.*

Technology	Attributes				Candidates in Preclinical Development	Candidates in Human Trials
	Single Dose	Licensed Platform	Speed	Current Scale		
DNA	No	No	Fast	Medium	Takis/Applied DNA Sciences/Evvivax Zydus Cadila	Inovio Pharmaceuticals, Phase 1 (NCT04336410)
Inactivated	No	Yes	Medium	Medium to high		Sinovac, Phase 1 (NCT04352608) Inactivated Beijing Institute of Biological Sciences/Wuhan Institute of Biological Sciences, Phase 1 (ChiCTR2000031809)
Live attenuated	Yes	Yes	Slow	High	Codagenix/Serum Institute of India	
Nonreplicating vector	Yes	No	Medium	High	GeoVax/BravoVax Janssen Pharmaceutical Companies Altimmune Greffex Vaxart ExpresS2ion	CanSino Biologics, Phases 1 and 2 (ChiCTR2000030906 and ChiCTR2000031781) University of Oxford, Phase 1/2 (NCT04324606)
Protein subunit	No	Yes	Medium to fast	High	WRAIR/U.S. Army Medical Research Institute of Infectious Diseases Clover Biopharmaceuticals Inc/GSK Vaxil Bio AJ Vaccines Genrex/EpiVax/University of Georgia Sanofi Pasteur Novavax Heat Biologics/University of Miami University of Queensland/GSK/ Baylor College of Medicine iBio/CC-Pharming	
Replicating viral vector	Yes	Yes	Medium	High	Zydus Cadila Institut Pasteur/Themis Tonix Pharma/Southern Research	
RNA	No	No	Fast	Low to medium	Fudan University/Shanghai JiaoTong University/RNACure Biopharma China CDC/Tongji University/Stermina Arcturus/Duke-NUS Imperial College London Curevac BioNTech/Pfizer	Moderna/NIAID (NCT04283461)
Uncertain					University of Pittsburgh University of Saskatchewan ImmunoPrecise MIGAL Galilee Research Institute Doherty Institute Tulane University	

COVID-19 Vaccine Development: An Interview With GeoVax

In the race to treat COVID-19, Georgia companies stake a claim

GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program



Asia Deal Watch: China’s BravoVax, US-based GeoVax Team Up On Coronavirus Vaccine - Paywall

The race to stop COVID-19 - GeoVax listed here



INFOGRAPHIC

THE RACE TO STOP COVID-19

As a new strain of coronavirus threatens public health systems across the globe, researchers are racing to develop a vaccine

DAWN CONNELLY & JULIA ROBINSON

In context

Compared with some outbreaks of novel respiratory disease, the death rate for coronavirus disease 2019 (COVID-19) is currently low. This could reduce further as the global outbreak progresses and milder cases are detected. Pandemic (H1N1) 2009 influenza was estimated to infect 1.6 billion people, with a death rate of 1 in 5,000 (0.02%); seasonal flu has a similar death rate, but infects up to 4 billion.

*Severe acute respiratory syndrome **Middle East respiratory syndrome

Case fatality rates for COVID-19

Symptoms and transmission

- Common symptoms: fever (98.6%); weakness (69.6%); cough (59.4%); muscle pains (34.8%); difficulties breathing (31.2%).
- Less common symptoms: headaches (6.5%), dizziness (9.4%), stomach pain (2.2%), diarrhoea (10.1%), nausea and vomiting (10.1%);
- Incubation period: 0–14 days;
- Severity: data from 44,000 cases of COVID-19 in China suggest that 80.9% of cases are mild, 13.8% are severe and 4.7% are critical. Severe cases are more prevalent in older people and those with an existing long-term condition, such as cardiovascular disease, diabetes, respiratory disease or hypertension;
- Transmission: person-to-person spread between close contacts (1.8 metres) through respiratory droplets;
- Diagnosis: COVID-19 is suspected based on clinical symptoms and relevant travel history or close contact with infected individuals. Cases are only confirmed when there is a positive laboratory test;
- Treatment: treatment of COVID-19 is symptomatic, such as providing oxygen. Medicines specifically licensed for COVID-19 are not currently available, but clinical trials of several antiviral drugs are being conducted in China.

Global takeover

31 December 2019: The first cases of pneumonia with unknown cause in Wuhan, China are reported to the World Health Organization (WHO)

7 January 2020: The Chinese authorities identify the novel coronavirus and temporarily name it "2019-nCoV", which is later changed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

10 January 2020: The Chinese Center for Disease Control and Prevention makes the genome of SARS-CoV-2 available

11 January 2020: The first COVID-19 death is reported in China

24 January 2020: The first case of person-to-person transmission of COVID-19 outside of China is reported in Vietnam

30 January 2020: The WHO declares the COVID-19 outbreak a public health emergency of international concern

31 January 2020: The first UK cases are confirmed

2 February 2020: The first COVID-19 death outside of China is reported in the Philippines

14 February 2020: China records a spike in cases after a broader definition of COVID-19 diagnosis is introduced

25 February 2020 For the first time, the number of new cases reported in China is overtaken by the number of cases reported in the rest of the world

28 February 2020: The WHO raises the global risk level to "very high"

THE PHARMACEUTICAL JOURNAL VOL 304 NO 7935 MARCH 2020

INFOGRAPHIC

Vaccine development

There are five main approaches being taken to develop a vaccine against SARS-CoV-2, with several biotechnology companies, academic organisations and pharmaceutical companies employing different technologies in the race to bring their vaccine candidate to clinical trials. The World Health Organization (WHO) hopes that a vaccine will be available by October 2021.

1. Viral vector vaccine:

- **Organisations working on vaccine:** Johnson & Johnson; Geovax Labs and BravoVax; University of Oxford and Advent Srl; Tonix Pharmaceuticals and Southern Research; Altimmune; Greffex; Vaxart; CanSino Biologics; Zydus Cadila; Institute Pasteur
- **Estimated date of first human trials:** June 2020

2. DNA vaccine:

- **Organisations working on vaccine:** Inovio Pharmaceuticals with Beijing Advaccine Biotechnology; Applied DNA Sciences, Takis Biotech and Evvivax; Zydus Cadila
- **Estimated date of first human trials:** April 2020

3. RNA vaccine:

- **Organisations working on vaccine:** CureVac; Moderna and US National Institute of Allergy and Infectious Diseases; Stermirna Therapeutics, Tongji University and Chinese Center for Disease Control and Prevention; Imperial College London
- **Estimated date of first human trials:** April 2020

4. Live-attenuated vaccine:

- **Organisations working on vaccine:** Codagenix with Serum Institute of India
- **Estimated date of first human trials:** By August 2020

5. Protein-based vaccine:

- **Organisations working on vaccine:** Novavax; Clover Biopharmaceuticals with GSK; Baylor College of Medicine, University of Texas Medical Branch, New York Blood Center and Fundan University, China; University of Saskatchewan, Canada; University of Queensland, Australia, and Dynavax; Vaxart; Generex; ExpreS2ion; Vaxil Bio; Sanofi Pasteur; iBio/CC-Pharming
- **Estimated date of first human trials:** By June 2020

Immune response:

- It is not known how strong the immune response needs to be to protect against SARS-CoV-2; therefore, some of the vaccines being developed may not work.
- Before candidates reach clinical trials, investigators must also ensure they induce protective immunity, not immunopathology, as was seen in early attempts to develop a SARS-CoV vaccine after it emerged in 2002.

MARCH 2020 NO 7935 VOL 304 THE PHARMACEUTICAL JOURNAL

Landscape of COVID-19 candidate vaccines